|
Gene: GABRE |
Gene summary for GABRE |
Gene summary. |
Gene information | Species | Human | Gene symbol | GABRE | Gene ID | 2564 |
Gene name | gamma-aminobutyric acid type A receptor subunit epsilon | |
Gene Alias | GABRE | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | P78334 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2564 | GABRE | CCII_1 | Human | Cervix | CC | 6.75e-12 | 5.72e-01 | 0.3249 |
2564 | GABRE | sample3 | Human | Cervix | CC | 1.71e-11 | 3.71e-01 | 0.1387 |
2564 | GABRE | T1 | Human | Cervix | CC | 3.98e-03 | 2.88e-01 | 0.0918 |
2564 | GABRE | T3 | Human | Cervix | CC | 1.04e-12 | 3.65e-01 | 0.1389 |
2564 | GABRE | LZE4T | Human | Esophagus | ESCC | 3.68e-13 | 3.33e-01 | 0.0811 |
2564 | GABRE | LZE5T | Human | Esophagus | ESCC | 4.20e-08 | 6.39e-01 | 0.0514 |
2564 | GABRE | LZE8T | Human | Esophagus | ESCC | 3.67e-15 | 2.51e-01 | 0.067 |
2564 | GABRE | LZE20T | Human | Esophagus | ESCC | 2.32e-10 | 3.53e-01 | 0.0662 |
2564 | GABRE | LZE22T | Human | Esophagus | ESCC | 5.23e-03 | 5.52e-01 | 0.068 |
2564 | GABRE | LZE24T | Human | Esophagus | ESCC | 2.38e-07 | 4.73e-01 | 0.0596 |
2564 | GABRE | LZE21T | Human | Esophagus | ESCC | 1.92e-16 | 7.20e-01 | 0.0655 |
2564 | GABRE | P1T-E | Human | Esophagus | ESCC | 1.43e-28 | 1.35e+00 | 0.0875 |
2564 | GABRE | P2T-E | Human | Esophagus | ESCC | 9.44e-11 | 1.80e-01 | 0.1177 |
2564 | GABRE | P4T-E | Human | Esophagus | ESCC | 2.07e-07 | 8.04e-02 | 0.1323 |
2564 | GABRE | P5T-E | Human | Esophagus | ESCC | 1.67e-05 | 8.08e-02 | 0.1327 |
2564 | GABRE | P8T-E | Human | Esophagus | ESCC | 2.60e-15 | 2.55e-01 | 0.0889 |
2564 | GABRE | P9T-E | Human | Esophagus | ESCC | 2.04e-39 | 1.25e+00 | 0.1131 |
2564 | GABRE | P10T-E | Human | Esophagus | ESCC | 1.85e-18 | 4.41e-01 | 0.116 |
2564 | GABRE | P15T-E | Human | Esophagus | ESCC | 6.71e-22 | 5.31e-01 | 0.1149 |
2564 | GABRE | P20T-E | Human | Esophagus | ESCC | 4.53e-16 | 4.77e-01 | 0.1124 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0472318 | Cervix | CC | Retrograde endocannabinoid signaling | 42/1267 | 148/8465 | 1.79e-05 | 1.42e-04 | 8.40e-05 | 42 |
hsa0472319 | Cervix | CC | Retrograde endocannabinoid signaling | 42/1267 | 148/8465 | 1.79e-05 | 1.42e-04 | 8.40e-05 | 42 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GABRE | SNV | Missense_Mutation | rs762535985 | c.697N>A | p.Glu233Lys | p.E233K | P78334 | protein_coding | tolerated(0.17) | benign(0.062) | TCGA-AJ-A23M-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | unknown | PD |
GABRE | SNV | Missense_Mutation | novel | c.986N>C | p.Lys329Thr | p.K329T | P78334 | protein_coding | tolerated(0.06) | probably_damaging(0.934) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GABRE | SNV | Missense_Mutation | c.1479N>A | p.Phe493Leu | p.F493L | P78334 | protein_coding | tolerated(1) | benign(0.022) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GABRE | SNV | Missense_Mutation | rs146075336 | c.1312N>T | p.Arg438Cys | p.R438C | P78334 | protein_coding | tolerated(0.11) | possibly_damaging(0.679) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GABRE | SNV | Missense_Mutation | rs756791363 | c.1172N>A | p.Arg391His | p.R391H | P78334 | protein_coding | tolerated(0.17) | benign(0.007) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
GABRE | SNV | Missense_Mutation | rs749967424 | c.998N>A | p.Arg333His | p.R333H | P78334 | protein_coding | deleterious(0.04) | probably_damaging(0.989) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
GABRE | SNV | Missense_Mutation | novel | c.460N>A | p.Asp154Asn | p.D154N | P78334 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
GABRE | SNV | Missense_Mutation | novel | c.29N>C | p.Leu10Pro | p.L10P | P78334 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.601) | TCGA-AP-A1DH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GABRE | SNV | Missense_Mutation | c.716N>A | p.Ser239Tyr | p.S239Y | P78334 | protein_coding | tolerated(0.23) | benign(0.108) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GABRE | SNV | Missense_Mutation | novel | c.250N>A | p.His84Asn | p.H84N | P78334 | protein_coding | tolerated(1) | benign(0.018) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | CHLORDIAZEPOXIDE | CHLORDIAZEPOXIDE | ||
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | CHEMBL591 | ETHCHLORVYNOL | ||
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | positive modulator | CHEMBL30219 | METHOHEXITAL SODIUM | |
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | FLUDIAZEPAM | FLUDIAZEPAM | ||
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | QUAZEPAM | QUAZEPAM | ||
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | agonist | CHEMBL979 | MEPROBAMATE | |
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | GABOXADOL | GABOXADOL | ||
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | positive modulator | CHEMBL931 | HALOTHANE | |
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | TRIAZOLAM | TRIAZOLAM | ||
2564 | GABRE | DRUGGABLE GENOME, ION CHANNEL | FLURAZEPAM | FLURAZEPAM |
Page: 1 2 3 4 5 6 7 8 9 10 |